Validation of non‐invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII
Liver International · 2023
DOI: 10.1111/liv.15632 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2023. Verfasst von Byeong Geun Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Esophageal and Gastric Varices, Hypertension, Portal, Elasticity Imaging Techniques. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Baveno VII consensus introduced the non‐invasive criteria of clinically significant portal hypertension (CSPH) using liver stiffness measurement (LSM). We evaluated the usefulness of the Baveno VII criteria to predict the risk of decompensation in patients with compensated advanced chronic liver disease (cACLD).
Methods
We conducted a retrospective cohort study of 1966 patients with cACLD. Patients were categorized into four groups (CSPH excluded ( n = 619), grey zone (low risk of CSPH ( n = 699), high risk of CSPH ( n = 207)), and CSPH included ( n = 441)) according to Baveno VII consensus. The risk of events was estimated using a Fine and Gray competing risk regression analysis, with liver transplantation and death as competing events. We calculated standardized hazard ratios (sHR) to assess the relative risk of decompensation.
Results
Among 1966 patients, 178 developed decompensations over a median follow‐up of 3.06 (IQR: 1.03–6.00) years. Patients with CSPH had the highest decompensation risk, followed by the grey zone high‐risk group, grey zone low‐risk group, and those without CSPH with 3‐year cumulative risks of 22%, 12%, 3.3%, and 1.4% respectively ( p < .001). Compared to CSPH excluded group, CSPH included group (sHR: 8.00, 95% CI: 4.00–16.0), grey zone high‐risk group (sHR: 6.57, 95% CI: 3.16–13.6), grey zone low‐risk group (sHR: 2.15, 95% CI: 1.04–4.41) had significantly higher risk of decompensation (Gray's test p < .01).
Conclusion
Non‐invasive diagnosis of CSPH according to the Baveno VII criteria can stratify the risk of decompensation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
ORCID-Profile: Byeong Geun Song, Geum-Youn Gwak, Dong Hyun Sinn
Zitieren
APA
Song, B. G., Goh, M. J., Kang, W., Gwak, G. Y., Paik, Y. H., Choi, M. S., Lee, J. H., Paik, S. W., & Sinn, D. H. (2023). Validation of non‐invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII. Liver International. https://doi.org/10.1111/liv.15632
Vancouver
Song BG, Goh MJ, Kang W, Gwak GY, Paik YH, Choi MS, et al. Validation of non‐invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII. Liver International. 2023. doi:10.1111/liv.15632
BibTeX
@article{Song2023,
author = {Song, Byeong Geun and Goh, Myung Ji and Kang, Wonseok and Gwak, Geum-Youn and Paik, Yong-Han and Choi, Moon Seok and Lee, Joon Hyeok and Paik, Seung Woon and Sinn, Dong Hyun},
title = {Validation of non‐invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII},
journal = {Liver International},
year = {2023},
doi = {10.1111/liv.15632}
}
EUVIMED